News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
July, 2025
July 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Eric K. Singhi: U.S. FDA Approved Taletrectinib for ROS1+ mNSCLC
Eric Singhi/X
Jun 12, 2025, 19:16

Eric K. Singhi: U.S. FDA Approved Taletrectinib for ROS1+ mNSCLC

Eric K. Singhi, Thoracic Medical Oncologist at MD Anderson Cancer Center, shared a post on X:

“U.S. FDA approves taletrectinib for ROS1+ mNSCLC.
Treatment-naïve:
– ORR: 90% (TRUST-I), 85% (TRUST-II)
– DOR ≥12 mo: 72%, 63%
TKI-pretreated:
– ORR: 52% (TRUST-I), 62% (TRUST-II)
– DOR ≥6 mo: 74%, 83%
Liver tox, ILD/pneumonitis, QTc, hyperuricemia, myalgia, fractures.”

Eric K. Singhi

More posts featuring Eric Singhi on OncoDaily.

cancer Eric K. Singhi FDA MD Anderson Cancer Center NSCLC OncoDaily Oncology Taletrectinib U.S. FDA
Special Coverage
Blog
Jul 18, 2025, 01:13
Get to Know Honami Naora and Her Ovarian Cancer Research Team - MD Anderson Cancer Center
Blog
Jul 18, 2025, 01:00
Why Submit an Abstract at the ESMO Immuno-Oncology Congress 2025?
Blog
Jul 18, 2025, 00:39
Domitille de La Gorce: Greetings from Ghana
Career
Jul 18, 2025, 00:10
Ammira Al-Shabeeb: We're Hiring a Data Scientist/Bioinformatician
Blog
Jul 17, 2025, 23:43
Olubukola Ayodele: An Inner Conviction That Drove Me Here
Blog
Jul 17, 2025, 23:17
7th Cancer Genomics, Multiomics, and Computational Biology Cretonference Returns - EACR
Blog
Jul 17, 2025, 21:13
Hadieh Eslampanah: Introductory course to the POEM and member benefits
Blog
Jul 17, 2025, 20:51
Applications are open for the Certificate of Competence in Breast Cancer - European School of Oncology
Career
Jul 17, 2025, 20:39
Sally Donaldson Started New Role As Senior Fellowships and Grants Manager at UICC
Insight
Jul 17, 2025, 20:26
Key Reason Some Cancer Patients Relapse After Receiving CAR-T Cell Therapy - Mayo Clinic
Blog
Jul 17, 2025, 19:54
Vahe Grigoryan: Our Abstract has been Accepted as a Poster Presentation at the ESMO 2025 Congress
Blog
Jul 17, 2025, 19:32
Amol Akhade: What You Think is the Best Way to Raise Critical Questions About a Published Trial?